[go: up one dir, main page]

MX2024006208A - Anticuerpo anti-trem2 y usos del mismo. - Google Patents

Anticuerpo anti-trem2 y usos del mismo.

Info

Publication number
MX2024006208A
MX2024006208A MX2024006208A MX2024006208A MX2024006208A MX 2024006208 A MX2024006208 A MX 2024006208A MX 2024006208 A MX2024006208 A MX 2024006208A MX 2024006208 A MX2024006208 A MX 2024006208A MX 2024006208 A MX2024006208 A MX 2024006208A
Authority
MX
Mexico
Prior art keywords
trem2 antibody
trem2
antibody
formulations
methods
Prior art date
Application number
MX2024006208A
Other languages
English (en)
Inventor
Spyridon Papapetropoulos
Evan Andrew Thackaberry
David K Stiles
Andrew J Marsh
Ryan O''MARA
Original Assignee
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigil Neuroscience Inc filed Critical Vigil Neuroscience Inc
Publication of MX2024006208A publication Critical patent/MX2024006208A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona anticuerpos anti-TREM2, formulaciones de los mismos, y métodos de uso de los mismos.
MX2024006208A 2021-11-22 2022-11-22 Anticuerpo anti-trem2 y usos del mismo. MX2024006208A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163264428P 2021-11-22 2021-11-22
GR20210100820 2021-11-22
US202263381897P 2022-11-01 2022-11-01
PCT/US2022/080342 WO2023092146A1 (en) 2021-11-22 2022-11-22 Anti-trem2 antibody and uses thereof

Publications (1)

Publication Number Publication Date
MX2024006208A true MX2024006208A (es) 2024-08-19

Family

ID=86397908

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006208A MX2024006208A (es) 2021-11-22 2022-11-22 Anticuerpo anti-trem2 y usos del mismo.

Country Status (12)

Country Link
US (1) US20250019437A1 (es)
EP (1) EP4437000A4 (es)
JP (1) JP2024540641A (es)
KR (1) KR20240134116A (es)
AU (1) AU2022389214A1 (es)
CA (1) CA3239455A1 (es)
CO (1) CO2024007674A2 (es)
CR (1) CR20240255A (es)
IL (1) IL312927A (es)
MX (1) MX2024006208A (es)
TW (1) TW202330614A (es)
WO (1) WO2023092146A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459952B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators
US12459953B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177322A4 (en) * 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته

Also Published As

Publication number Publication date
CR20240255A (es) 2025-01-27
CA3239455A1 (en) 2023-05-25
IL312927A (en) 2024-07-01
JP2024540641A (ja) 2024-10-31
TW202330614A (zh) 2023-08-01
US20250019437A1 (en) 2025-01-16
KR20240134116A (ko) 2024-09-06
EP4437000A1 (en) 2024-10-02
AU2022389214A1 (en) 2024-06-13
EP4437000A4 (en) 2025-12-03
WO2023092146A1 (en) 2023-05-25
CO2024007674A2 (es) 2024-09-09

Similar Documents

Publication Publication Date Title
PH12020551716A1 (en) Anti-ror antibody constructs
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CO2018010855A2 (es) Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2019004690A (es) Constructos de anticuerpos.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
EA201991876A1 (ru) Антитела против фактора d и их применения
CO2025007355A2 (es) Anticuerpo anti-trem2 y usos del mismo
MX2018012434A (es) Nuevos anticuerpos anti-sirpa y sus aplicaciones terapeuticas.
EA202192101A1 (ru) Соединения и их применение
CO2024007674A2 (es) Anticuerpo anti-trem2 y usos del mismo
SA523450167B1 (ar) أجسام مضادة لعامل التحول الوسيطي الظهاري واستخداماتها
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
CO2022019225A2 (es) Anticuerpos anti-hbv y métodos de uso
BR112022009587A2 (pt) Anticorpo anti-pcsk9 e uso do mesmo
CR20240526A (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
EA202192418A1 (ru) Способы лечения al-амилоидоза
CL2021002836A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos (divisional de la solicitud n° 201900424)
MX2024002187A (es) Anticuerpos y conjugados de nectina-4.